GCGwo-Shing Chen

Gwo-Shing Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gwo-Shing Chen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • C-C.E. Lan

    Department of Dermatology, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd, Kaohsiung, Taiwan

    2 shared publications
  • H-S. Yu

    Department of Dermatology, Kaohsiung Medical University, 100 Shih‐Chuan 1st Rd, Kaohsiung, Taiwan *Department of Dermatology, College of Medicine, National Taiwan University, Taipei, Taiwan

    2 shared publications
  • Shu-Mei Huang

    Department of Dermatology, Kaohsiung Medical University Hospital, Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

    2 shared publications
  • Cheng-Chen Eric Lan

    Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

    1 shared publication
  • Cheng‐Che E. Lan

    Department of Dermatology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

    1 shared publication
  • Chieh‐Chen Huang

    Department of Dermatology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, National Taiwan University Hospital, Taipei, Taiwan

    1 shared publication

Latest Publications

  • Open Access

    Irradiance-dependent UVB Photocarcinogenesis

    by Cheng-Che E Lan, Ching-Shuang Wu, Shu-Mei Huang, Chin-Han Wu, Hsiao-Chi Lai, Yu-Ting Peng, Pao-Sheng Hou, Hui-Jun Yang, Gwo-Shing Chen

    Ultraviolet B (UVB) radiation from the sun may lead to photocarcinogenesis of the skin. Sunscreens were used to protect the skin by reducing UVB irradiance, but sunscreen use did not reduce sunburn episodes. It was shown that UVB-induced erythema depends on surface exposure but not irradiance of UVB. We previously showed that irradiance plays a critical role in UVB-induced cell differentiation. This study investigated the impact of irradiance on UVB-induced photocarcinogenesis. For hairless mice receiving equivalent exposure of UVB radiation, the low irradiance (LI) UVB treated mice showed more rapid tumor development, larger tumor burden, and more keratinocytes harboring mutant p53 in the epidermis as compared to their high irradiance (HI) UVB treated counterpart. Mechanistically, using cell models, we demonstrated that LI UVB radiation allowed more keratinocytes harboring DNA damages to enter cell cycle via ERK-related signaling as compared to its HI UVB counterpart. These results indicated that at equivalent exposure, UVB radiation at LI has higher photocarcinogenic potential as compared to its HI counterpart. Since erythema is the observed sunburn at moderate doses and use of sunscreen was not found to associate with reduced sunburn episodes, the biological significance of sunburn with or without sunscreen use warrants further investigation.


  • FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin

    by C-C.E. Lan, Y-H. Kao, S-M. Huang, H-S. Yu, G-S. Chen

    Tacrolimus ointment (FK506) has been used in recent years for the treatment of atopic dermatitis (AD), with favourable results. Most of the therapeutic efficacy of FK506 in AD has been attributed to its immunomodulatory effects on different immune cell types, but its effects on keratinocytes (KCs) have rarely been discussed. Studies have shown that low expression of transforming growth factor (TGF)-beta and high expression of nitric oxide synthase (NOS) are implicated in the pathogenesis of AD. To investigate the direct effects of FK506 on KCs in terms of TGF-beta and inducible NOS (iNOS), and to explore the interactions between TGF-beta and iNOS in the KC system. Cultured human KCs treated with different concentrations of FK506 were used for investigation. The changes in the KC system induced by FK506 were documented in terms of TGF-beta and iNOS using enzyme-linked immunosorbent assay and Western blotting techniques, respectively. The gene expression of both TGF-beta and iNOS was also determined. A certain amount of tumour necrosis factor (TNF)-alpha was introduced to mimic atopic skin in vivo. Our results showed that the release of TGF-beta was upregulated in FK506-treated KCs, particularly in the presence of TNF-alpha, while the expression of iNOS was downregulated. The gene expression of iNOS was also downregulated, as shown by reverse transcriptase-polymerase chain reaction analysis. However, the addition of TNF-alpha did not further downregulate the expression of iNOS protein, suggesting that FK506 may regulate TGF-beta and iNOS through different pathways. Our findings indicate that the direct effects of FK506 on KCs probably contribute to its therapeutic efficacy in the treatment of AD.


  • Clear cell eccrine porocarcinoma with extensive cutaneous metastasis and peripheral lymphocyte dysfunction

    by C-C.E. Lan, H-S. Yu, W-T. Liao, R.C-C. Hsu, J-C. Chung, K-B. Tsai, G-S. Chen

    An 81‐year‐old woman came to our clinic (Department of Dermatology, Kaohsiung Medical University, Kaohsiung, Taiwan) with multiple erythematous, indurated papules over the left side of her face. Two years earlier, the patient had a skin biopsy done at a similar anatomical area with the histopathological diagnosis of Bowen's disease. After reviewing surgical specimens and confirming no systemic involvement, clear cell eccrine porocarcinoma with extensive cutaneous metastasis has been diagnosed. In addition, the peripheral blood lymphocyte function of the patient was evaluated. The expression of interleukin‐2 receptors on lymphocytes after stimulation is abnormal compared with the age‐matched normal control and a patient with cutaneous squamous cell carcinoma. This clinical manifestation of eccrine porocarcinoma is exceptional, and lymphocyte dysfunction in this patient has probably contributed to extensive cutaneous metastasis.


  • Open Access

    Tacrolimus Ointment for the Treatment of Atopic Dermatitis: Report of First Clinical Experience in Taiwan

    by Cheng‐Che E. Lan, Chien‐Te Lin, Gwo‐Shing Chen, Chieh‐Chen Huang, Yu‐Ting Chen, Li‐Fang Wang

    Atopic dermatitis (AD) is a pruritic recurring inflammatory skin disease. Recently, topical tacrolimus has been developed to treat AD. This report presents the first clinical experience with topical tacrolimus in Taiwan. This open-label, single-arm study was conducted at three centers from February to May 2002. The duration of each individual treatment was 4 weeks. Two groups were defined: pediatric and adult. Efficacy was evaluated on the basis of the physician's global evaluation at the end of treatment. Success was defined as at least 50% improvement. Other evaluations included the Eczema Area and Severity Index (EASI), the percentage of body surface area (BSA) involved, the patient's assessment of pruritus, and the patient's assessment of overall response. Safety profile was established by monitoring changes in hematology and biochemistry profiles and tacrolimus concentration in blood. All adverse events were recorded. Twenty-six pediatric patients and 42 adult patients were enrolled. Overall success rates were 80.8% and 82.1% in the pediatric and adult groups, respectively. The declines in EASI, percentage of BSA affected, and patient's assessment of pruritus were significant (p < 0.001); 88% and 100% of pediatric and adult patients, respectively, reported a favorable response to treatment. Changes in blood samples were unremarkable. Of pediatric and adult patients, 61.5% and 76.2%, respectively, reported adverse events. The most common adverse event reported was skin burning, which did not result in discontinuation of therapy. This report reveals that tacrolimus ointment is effective and safe for the treatment of AD in Taiwanese patients.